NASDAQ:LFCR Lifecore Biomedical (LFCR) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free LFCR Stock Alerts $7.18 -0.20 (-2.71%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$7.18▼$7.5350-Day Range$6.16▼$8.5552-Week Range$1.80▼$11.45Volume67,169 shsAverage Volume126,707 shsMarket Capitalization$217.70 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Lifecore Biomedical alerts: Email Address Lifecore Biomedical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside32.3% Upside$9.50 Price TargetShort InterestBearish5.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.14Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.10) to $0.22 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.65 out of 5 starsMedical Sector716th out of 947 stocksPharmaceutical Preparations Industry331st out of 431 stocks 3.3 Analyst's Opinion Consensus RatingLifecore Biomedical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Lifecore Biomedical has a forecasted upside of 32.3% from its current price of $7.18.Amount of Analyst CoverageLifecore Biomedical has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.88% of the float of Lifecore Biomedical has been sold short.Short Interest Ratio / Days to CoverLifecore Biomedical has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.Change versus previous monthShort interest in Lifecore Biomedical has recently increased by 0.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLifecore Biomedical does not currently pay a dividend.Dividend GrowthLifecore Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LFCR. Previous Next 3.4 News and Social Media Coverage News SentimentLifecore Biomedical has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lifecore Biomedical this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for LFCR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Lifecore Biomedical to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.Percentage Held by Insiders14.61% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.85% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.10) to $0.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lifecore Biomedical is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lifecore Biomedical is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLifecore Biomedical has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Lifecore Biomedical Stock (NASDAQ:LFCR)Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is based in Chaska, Minnesota.Read More LFCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LFCR Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comLFCR Apr 2024 7.500 callFebruary 17, 2024 | finance.yahoo.comLFCR Mar 2024 10.000 callMarch 19, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: February 17, 2024 | finance.yahoo.comLFCR Mar 2024 10.000 putFebruary 16, 2024 | msn.comLifecore Biomedical receives Nasdaq notice of delistingFebruary 16, 2024 | finance.yahoo.comLifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to AppealFebruary 16, 2024 | globenewswire.comLifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to AppealFebruary 6, 2024 | msn.comStrength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?March 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.January 30, 2024 | finance.yahoo.comShould You Hold Lifecore Biomedical (LFCR) for Long Term?January 12, 2024 | msn.comLifecore Biomedical receives Nasdaq notice for delayed quarterly reportsJanuary 10, 2024 | finance.yahoo.comEven after rising 12% this past week, Lifecore Biomedical (NASDAQ:LFCR) shareholders are still down 39% over the past five yearsJanuary 8, 2024 | finance.yahoo.comHere’s Why Cove Street Capital Reduced its Position in Lifecore Biomedical (LFCR)January 7, 2024 | ca.finance.yahoo.comLifecore Biomedical, Inc. (LFCR)January 5, 2024 | finanznachrichten.deLifecore Biomedical, Inc.: Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial ArrangementsJanuary 5, 2024 | finance.yahoo.comLifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial ArrangementsDecember 25, 2023 | finance.yahoo.comLifecore Biomedical, Inc. (LDE.F)December 13, 2023 | finanznachrichten.deLifecore Biomedical, Inc.: Lifecore Biomedical Provides Business UpdateDecember 13, 2023 | finance.yahoo.comLifecore Biomedical Provides Business UpdateNovember 20, 2023 | finance.yahoo.comCompany Reaches Favorable Resolution Regarding Previously-Disclosed Investigation of Formerly-Held Subsidiary Yucatan FoodsNovember 17, 2023 | finance.yahoo.comLifecore Biomedical Avoids U.S. Prosecution Over Alleged Mexico BribesOctober 24, 2023 | finance.yahoo.comHere’s Why Lifecore Biomedical (LFCR) Declined in Q3October 20, 2023 | seekingalpha.comLifecore Biomedical receives notice from Nasdaq regarding delayed annual reportOctober 17, 2023 | finance.yahoo.comSHL Medical and Lifecore Biomedical enter co-marketing partnership agreementOctober 10, 2023 | finance.yahoo.comLifecore Biomedical Provides Update for Development Portfolio and Timing of Delayed FilingsOctober 10, 2023 | finance.yahoo.comHere’s Why Cove Street Capital Sold Lifecore Biomedical (LFCR)September 28, 2023 | finance.yahoo.comWill Lifecore Biomedical (LFCR) Report Negative Q1 Earnings? What You Should KnowSee More Headlines Receive LFCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/18/2024Fiscal Year End5/31/2024Next Earnings (Estimated)6/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LFCR CUSIPN/A CIK1005286 Webwww.lifecore.com Phone(800) 454-1355Fax650-368-9818Employees689Year FoundedN/APrice Target and Rating Average Stock Price Target$9.50 High Stock Price Target$10.00 Low Stock Price Target$9.00 Potential Upside/Downside+32.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$103.27 million Price / Sales2.11 Cash Flow$4.01 per share Price / Cash Flow1.79 Book Value$3.08 per share Price / Book2.33Miscellaneous Outstanding Shares30,320,000Free Float25,892,000Market Cap$217.70 million OptionableOptionable Beta1.07 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. James G. Hall (Age 61)CEO, President & Director Comp: $711.57kMr. John D. Morberg (Age 60)Executive VP & CFO Comp: $443.43kDr. Albert D. Bolles Ph.D. (Age 66)President of Curation Foods, Inc. Comp: $688.19kMr. Steve W. LaningaVice President of OperationsDr. Kipling Thacker Ph.D. (Age 69)VP & Chief Scientist Mr. Aaron PerlitshDirector of Internal Audit & Chief Compliance OfficerMr. Darren M. HieberSenior Vice President of Corporate Development & PartnershipsMs. Kara MorleySenior Vice President of Human ResourcesMs. Jackie Q. KleckerExecutive VP & GMMr. Matt AugustsonSenior Vice President of Information TechnologyMore ExecutivesKey CompetitorsAmylyx PharmaceuticalsNASDAQ:AMLX23andMeNASDAQ:ME2seventy bioNASDAQ:TSVTAnnexonNASDAQ:ANNXZevra TherapeuticsNASDAQ:ZVRAView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Bought 22,558 shares on 3/1/2024Ownership: 0.111%Prelude Capital Management LLCBought 22,745 shares on 2/15/2024Ownership: 0.075%Barclays PLCSold 11,403 shares on 2/15/2024Ownership: 0.064%Wolverine Trading LLCSold 11,200 shares on 2/15/2024Ownership: 0.000%Citadel Advisors LLCSold 44,400 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions LFCR Stock Analysis - Frequently Asked Questions Should I buy or sell Lifecore Biomedical stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lifecore Biomedical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LFCR shares. View LFCR analyst ratings or view top-rated stocks. What is Lifecore Biomedical's stock price target for 2024? 2 brokers have issued 12 month target prices for Lifecore Biomedical's stock. Their LFCR share price targets range from $9.00 to $10.00. On average, they predict the company's share price to reach $9.50 in the next year. This suggests a possible upside of 32.3% from the stock's current price. View analysts price targets for LFCR or view top-rated stocks among Wall Street analysts. How have LFCR shares performed in 2024? Lifecore Biomedical's stock was trading at $6.19 at the start of the year. Since then, LFCR shares have increased by 16.0% and is now trading at $7.18. View the best growth stocks for 2024 here. When is Lifecore Biomedical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024. View our LFCR earnings forecast. Who are Lifecore Biomedical's major shareholders? Lifecore Biomedical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Greenhaven Road Investment Management L.P. (7.81%), Cove Street Capital LLC (3.00%), Visionary Wealth Advisors (1.64%), DCF Advisers LLC (0.86%), Royal Bank of Canada (0.35%) and UBS Group AG (0.25%). How do I buy shares of Lifecore Biomedical? Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LFCR) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.